Simple blood test may open door to gene therapy for duchenne boys
NCT ID NCT05683379
First seen Jun 27, 2026 · Last updated Jul 08, 2026 · Updated 4 times
Summary
This study screens males with Duchenne muscular dystrophy (ages 0 to under 25) for antibodies against AAV8, a virus used in some gene therapies. The goal is to find out how many have these antibodies and to identify who might be eligible for future gene therapy trials. No treatment is given; it is purely an observational screening study.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DUCHENNE MUSCULAR DYSTROPHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Rare Disease Research
Atlanta, Georgia, 30329, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a lower steroid dose preserve strength in young boys with DMD?
- Can a targeted infusion slow muscle decline in duchenne? a new trial aims to find out.
- Can a massive patient database unlock new treatments for muscular dystrophy?
- Umbilical cord stem cells aim to slow muscle loss in duchenne boys
- Experimental drug aims to preserve arm and lung function in boys with advanced duchenne
- Experimental drug KER-065 aims to slow muscle decline in duchenne muscular dystrophy